An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients

Ichiro Kawada, Kenzo Soejima, Hideo Watanabe, Ichiro Nakachi, Hiroyuki Yasuda, Katsuhiko Naoki, Masafumi Kawamura, Keisuke Eguchi, Koichi Kobayashi, Akitoshi Ishizaka

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Introduction: Epidermal growth factor receptor (EGFR) mutations are strong determinants of tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancers (NSCLCs). Currently available methods of EGFR mutation detection rely on direct sequencing. Here, we describe the use of an alternative way to screen EGFR mutations. Methods: A total of 109 frozen tumor specimens from NSCLC patients were obtained. For mutational analysis of EGFR exons 18, 19, and 21, reverse transcription-polymerase chain reaction was performed on the cDNA using original primers designed for restriction fragment length polymorphism (RFLP). Results: EGFR mutations were detected in 37 patients (34%) by both RFLP and direct sequencing except one case in which it was detected only by RFLP. EGFR mutations were more frequently observed to be significant by multivariate analysis in patients with adenocarcinoma (OR = 5.56), no-smoking history (OR = 4.34), and 65-year-old or younger (OR = 2.64), but not in women (OR = 1.14). Among 37 patients, 18 were treated with gefitinib and 9 responded to the treatment. One patient without any mutation responded. Conclusion: RFLP is a useful method for screening EGFR mutations and can also be applied to predicting the sensitivity of NSCLC patients to EGFR-tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)1096-1103
Number of pages8
JournalJournal of Thoracic Oncology
Issue number10
Publication statusPublished - 2008 Oct


  • EGFR mutation
  • Non-small cell lung cancer
  • RFLP

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients'. Together they form a unique fingerprint.

Cite this